Welcome to our dedicated page for KESTRA MED TECHNOLOGIES news (Ticker: KMTS), a resource for investors and traders seeking the latest updates and insights on KESTRA MED TECHNOLOGIES stock.
Kestra Medical Technologies Ltd (KMTS) delivers innovative wearable cardiac solutions through its ASSURE WCD and integrated Cardiac Recovery System. This news hub provides stakeholders with essential updates on the company developments shaping cardiovascular care technology.
Access timely announcements including FDA clearances, clinical trial results, partnership agreements, and financial disclosures. Our curated collection serves investors and healthcare professionals tracking advancements in life-saving wearable defibrillator technology and digital health integration.
Key updates cover regulatory milestones, product enhancements, peer-reviewed study publications, and strategic collaborations. Discover how KMTS continues to address sudden cardiac arrest risks through engineering innovations and evidence-based patient support systems.
Bookmark this page for centralized access to verified corporate communications. Check regularly for developments impacting the wearable medical device sector and KMTS's position within the cardiovascular care market.
Kestra Medical Technologies presented new real-world data for their ASSURE Wearable Cardioverter Defibrillator (WCD) at Heart Rhythm 2025 in San Diego. The study focused on outcomes in a community-based setting using an advanced practice provider (APP)-driven protocol.
Key findings demonstrate:
- High patient compliance with 23.3 hours median daily wear time
- Consistent usage beyond 90 days
- 4% of patients showed ventricular arrhythmias detection
- Successful implementation of APP-driven care model
- Effective continuity of care through ICD placement or hospitalization when needed
The study validates ASSURE's effectiveness in protecting patients from sudden cardiac arrest through both clinical performance and patient engagement. The results highlight the success of structured, team-based approaches in expanding access to cardiac care within community settings.
Kestra Medical Technologies (Nasdaq: KMTS) announced its participation in Heart Rhythm 2025, the annual Heart Rhythm Society meeting, scheduled for April 24-27 at the San Diego Convention Center. This marks the company's first major industry showcase following its recent IPO.
The company will showcase its ASSURE® system, a wearable medical device that combines defibrillation therapy with diagnostic and patient support capabilities. The exhibition will feature an immersive in-booth experience demonstrating the system's role in protecting patients at risk of sudden cardiac arrest.
During the event, Kestra will present new real-world clinical data about the ASSURE system's impact and continue its sponsorship of the Women in EP Luncheon for the fourth consecutive year.
Kestra Medical Technologies (NASDAQ: KMTS) reported strong Q3 FY25 financial results with revenue of $15.1 million, up 82% year-over-year. The company achieved a significant improvement in gross margin to 43.4% from 10.6% in the prior year period.
Key highlights include 3,459 prescriptions written for the ASSURE® system, representing a 51% increase. The company successfully completed its IPO in March 2025, raising $205.2 million in net proceeds. Kestra expanded its insurance coverage network, now reaching over 285 million health plan members in the United States.
For fiscal year 2025 ending April 30, Kestra projects revenue between $58.0-58.5 million, indicating approximately 109-110% growth compared to FY24. However, the company reported a GAAP net loss of $21.8 million and an adjusted EBITDA loss of $16.3 million for Q3 FY25.
Nalu Medical has appointed Raymond W. Cohen as chairman of its board of directors. Cohen previously served as CEO and board member of Axonics, a medical device company he co-founded in 2013 and took public in 2018. Under his leadership, Axonics achieved recognition as the fastest-growing company in the Americas by Deloitte and Financial Times in 2021 and 2022.
Cohen recently oversaw Axonics' $3.7 billion sale to Boston Scientific (NYSE: BSX) in November 2024. He also served as chairman of SoniVie, which was sold to BSX for $600 million in March 2025. Currently, he serves on the board of Kestra Medical Technologies (Nasdaq: KMTS), which recently completed a $232 million IPO.
Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has scheduled its third quarter fiscal 2025 financial results announcement for Monday, April 14. The company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss the results. Investors can access both live and archived versions of the webcast through the 'Events' section of the investor relations website, with registration recommended at least 10 minutes before the call.
Kestra Medical Technologies (KMTS), a wearable medical device and digital healthcare company, has announced the full exercise of the underwriters' over-allotment option in its Initial Public Offering (IPO). The underwriters purchased an additional 1,782,352 shares at $17.00 per share.
Following this over-allotment exercise, the total IPO size reached 13,664,704 shares, generating total gross proceeds of approximately $232 million before deducting underwriting discounts, commissions, and other offering expenses.
The offering's lead bookrunners were BofA Securities, Goldman Sachs & Co. , and Piper Sandler, with Wells Fargo Securities and Stifel acting as bookrunners, and Wolfe | Nomura Alliance as co-manager. The registration statement became effective on March 5, 2025.
Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has successfully completed its upsized initial public offering (IPO). The company offered 11,882,352 common shares at $17.00 per share, generating total gross proceeds of approximately $202 million before deducting underwriting discounts and other expenses.
Trading of Kestra's common shares commenced on the Nasdaq Global Select Market on March 6, 2025, under the ticker symbol 'KMTS'. The IPO was led by BofA Securities, Goldman Sachs & Co. , and Piper Sandler as lead bookrunners, with Wells Fargo Securities and Stifel acting as bookrunners and Wolfe | Nomura Alliance as co-manager.
Kestra Medical Technologies, a wearable medical device and digital healthcare company, has announced the pricing of its upsized IPO of 11,882,352 common shares at $17.00 per share. The shares will trade on the Nasdaq Global Select Market under the symbol 'KMTS' starting March 6, 2025.
The company expects to raise approximately $202 million in gross proceeds before deducting underwriting costs and other expenses. Underwriters have a 30-day option to purchase up to 1,782,352 additional shares at the IPO price. The offering is expected to close on March 7, 2025.
Lead bookrunners include BofA Securities, Goldman Sachs & Co. , and Piper Sandler, with Wells Fargo Securities and Stifel as bookrunners and Wolfe | Nomura Alliance as co-manager.
Kestra Medical Technologies, a wearable medical device and digital healthcare company, has announced the launch of its Initial Public Offering (IPO). The company plans to offer 10,000,000 common shares with an expected price range of $14.00 to $16.00 per share.
Underwriters will have a 30-day option to purchase up to 1,500,000 additional shares at the IPO price, less underwriting discounts and commissions. Kestra has applied to list on the Nasdaq Global Select Market under the symbol 'KMTS'.
The offering is led by BofA Securities, Goldman Sachs, and Piper Sandler as lead bookrunners, with Wells Fargo Securities and Stifel as bookrunners and Wolfe | Nomura Alliance as co-manager.
FAQ
What is the current stock price of KESTRA MED TECHNOLOGIES (KMTS)?
What is the market cap of KESTRA MED TECHNOLOGIES (KMTS)?
